Pending — not yet graded
“Within the pharmaceutical sector, Nischal Maheshwari favors the CDMO sub-segment, which he sees growing very rapidly. Laurus Labs is his top pick in this space, and he holds it in his portfolio.”
Nischal Maheshwari’s track record: 8 graded calls · 95% CI 14–69%
Laurus Labs LimitedBullishCalled 13 Jan 2026
This call hasn't reached its evaluation window yet — the HIT/MISS verdict will appear here once it's graded against real price data. Save it above to find it again from your profile.
Read the original articleSee Nischal Maheshwari’s full track record